Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Depression and Anxiety in the Aetiology and Prognosis of Specific Cardiovascular Disease Syndromes: a CALIBER Study

22 novembre 2010 aggiornato da: University College, London

Depression and Anxiety in the Aetiology and Prognosis of Specific Cardiovascular Disease Syndromes: a CALIBER Study Using Linked GPRD-MINAP-HES Data

People report feeling sad and low (depression) or worried (anxiety) appear more likely to subsequently suffer a heart attack, or angina. However it is not known whether depression or anxiety actually causes heart disease. If these mental health problems and heart disease were cause and effect this has important implications for world health. Previous research on this topic has had several limitations. First, most studies have studied heart disease as if it were one thing. There is a need for studies which distinguish different types of heart disease (e.g. different types of heart attack, angina) which may be linked to mental health problems in different ways. Second, it is not clear whether symptoms of heart disease come before the depression or anxiety or the other way round? Much of the available research cannot look at this in detail because they rely on data from occasional snapshots of study populations rather than a continuous record. The investigators propose to use the linkage of the national registry of coronary events to general practice records in the GPRD, which will allow us to address these limitations. The investigators research will help us understand better whether mental health problems cause the onset of different types of coronary disease.

Panoramica dello studio

Descrizione dettagliata

This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the NIHR and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (GPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).

Overall aim

To elucidate the role of depression and anxiety in the aetiology and prognosis of specific acute and chronic coronary disease phenotypes.

Background

Coronary disease and depression are major causes of mortality and morbidity globally and so the public health impact of a causal association between the two is profound1. But our meta-analysis of 22 aetiologic cohort studies (4016 events) the presence of depression was associated with a 70% increased risk of CHD events. This systematic review, and others, identified several limitations of existing research, including a) clinical phenotype resolution: broad aggregates of CHD, rather than specific coronary phenotypes, b) small size, with insufficient event numbers to compare risks in women and men, c) temporal resolution: Single time point of exposure to depression (usually prevalent); unclear temporal relation between the onset of symptoms of depression and the onset of symptoms associated with coronary disease and lack of studies assessing whether exposure to depression prior to the onset of any symptomatic coronary disease influences the prognosis (future progression) of coronary disease once established, d) incomplete and inconsistent assessment of potential confounders or mediators: unclear role of social deprivation, smoking, alcohol and other behaviours which may confound the association; unclear role of detection, treatment and control of cardiovascular risk among patients with depression and lack of consideration of co-existing psychiatric morbidities.

Study design

Observational study, using cohort and case series analyses in initially healthy populations, and among patients with specific manifestations of coronary disease.

Sample size calculations

We have ample statistical power for our main hypotheses. For example we will estimate a relative risk for the effect of depression (vs not) on STEMI, and compare this with the relative risk for the effect of depression vs not on non-STEMI. Assuming depression exposure prevalence of 10%, 500 linked cases of each type and alpha of 0.01, we will be able to distinguish a relative risk of, say 1.7.

Data analysis Our overall analytic approach involves the distinction between different coronary disease phenotypes which form the endpoints of aetiologic, and the start-points of prognostic, analyses and between different temporal patterns of evolution of risk. Furthermore we will consider the separate, and joint, effects of depression and anxiety, distinguishing between a solitary measure and the cumulative impact of serial measures, on the specific coronary disease phenotypes.

A structured Statistical Analytic Protocol detailing how we will analyse the data and to what extent analytic choices are pre-specified, can be made available on request.

Expected value of results

This provides an opportunity to investigate large scale the association of depression with specific coronary syndromes comes from the linkage of GPRD to MINAP.

Tipo di studio

Osservativo

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • London, Regno Unito, WC1E 6BT
        • Clinical Epidemiology Group, University College London

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population will include all adults (18+) in GPRD registered in up-to-standard practices with at least 1 year of up to standard follow up. Analyses will focus on the ~200 practices which have consented to linkage with HES and MINAP. Essentially we will define an aetiological cohort - whole population - free of any coronary syndrome at start of follow up. Patients within this cohort are followed for the aetiologic endpoint of a first specific coronary syndrome (see below). This aetiologic endpoint is the prognostic start-point; such patients will then be followed for subsequent specific coronary syndromes and death. We will focus analyses on patients with at least a year follow up data before and their endpoint. As in a conventional cohort study we will define according to exposure history.

Descrizione

Inclusion Criteria:

  • Aged >18 years
  • Patient in a GPRD registered practice that has consented to the linkage process
  • Patients are free of any coronary syndrome at the start of follow-up

Exclusion Criteria:

  • Less than 1 year of follow-up before their end-point

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Depression, anxiety

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Chronic stable angina
Lasso di tempo: 1 year from date of first presentation
1 year from date of first presentation

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Coronary artery bypass graft (CABG)
Lasso di tempo: 1 year from date of first presentation
1 year from date of first presentation
Acute, non-fatal ST Elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina
Lasso di tempo: 1 year from date of first presentation
1 year from date of first presentation
Death (including sudden death)
Lasso di tempo: 1 year from date of first presentation
1 year from date of first presentation
Stroke
Lasso di tempo: 1 year from first presentation
1 year from first presentation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Harry Hemingway, FRCP, University College, London

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 gennaio 2010

Completamento primario (Anticipato)

1 dicembre 2013

Completamento dello studio (Anticipato)

1 dicembre 2014

Date di iscrizione allo studio

Primo inviato

11 novembre 2010

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2010

Primo Inserito (Stima)

15 novembre 2010

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

23 novembre 2010

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 novembre 2010

Ultimo verificato

1 gennaio 2010

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CALIBER 09-10
  • Wellcome Trust 086091/Z/08/Z (Altro numero di sovvenzione/finanziamento: Wellcome Trust grant)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi